In considering that VEGF is continuously expressed throughout tumor progression in facilitating tumor angiogenesis 21, an interesting question thus emerges: for patients that fail to the cetuximab-based first-line combination treatment, which is an optimal choice of further-line treatment: cetuximab continuation? The gene discussed is VEGFA; the disease is neoplasm.